Drug intelligence / Profile preview

YUAN-03

Development stage: Preclinical
Lead developer: AMS BioteQ
Modality: Small Molecules
Administration: Oral

Overview

YUAN-03 is a preclinical-stage small molecule antiviral candidate developed by AMS BioteQ. It is designed to target human coronaviruses, including SARS-CoV-2 and its variants, as well as the common cold coronavirus hCoV-OC43. The drug is part of AMS BioteQ's pipeline focusing on infectious diseases and is currently undergoing preclinical evaluation for its efficacy against respiratory viral infections.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)PLpro (Papain-like protease)

Beyond the preview

Go deeper on YUAN-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YUAN-03.

Explore the full profile